I first saw it in the endocyte's Analyst day presentation 2-3 years back. Since then we didn't hear much until now.
You may Google and find the analyst day ppt
There is no time limit.
A patent app. prosecution typically 1-3 years, but can take several years (e.g. Enbrel patent was granted after 17 years from the date of filing!!)
So you never know.
Though one can keep track through public PAIR from USPTO website reg. status of patent application.
From my limited knowledge being a Formulation Scientist for last 6+ years, I expect the Cmax to be lowered and AUC either lowered/improved compared to oral solution. Anyways, they shall present it positively.
They didn't sell when Merck was probably interested to buy the whole company (in my opinion, Merck was interested in buying it whole before the partnership deal with ECYT).
A BO doesn't make sense as the buyer wouldn't have much visibility into the future of the ECYT pipeline, especially after PROCEED failure. For ECYT selling right now wouldn't yield the right value.
Even EC145 used to produce cures in preclinical studies (alone or combo with PLD).
A PR or CR in the current phase 1 will make some serious difference.
1. Folate-DNA alkylator (much more potent than folate-tubulysin) to enter phase 1 in 2017.
Single dose has shown cures in preclinical models!
2. They treated an arthritic dog (who was barely able to walk) with their antiinflammatory compound and guess what? The dog started walking-jumping-running in 6 weeks! This drug will enter clinic in late 2017 (I believe 2018 to be more conservative).
This reminds me of years old data of folate-aminopterin which was found more effective than Enbrel ($8bn drug). I don't have the link for ready reference but you can Google it. I guess they have been improving this compound over the past few years and finally have a version that can be studied in human.
3. They are not sure (and so don't want to predict) when they might achieve MTD for folate or PSMA drug. I used to expect some significant efficacy data at ASCO which seems less likely. We will have some data by YE16 for sure.
Conclusion: Long term hold - massive potential (10x-20x) in 4-5 years.
They present at lot of places but do not PR it.
They did present at JP Morgan in January, still no PR. So nothing exciting :(
That's not patented yet, it's just an patent application, big difference between an application and a granted patent.
I wd be happy if that's true :) (MTD not reached yet)
They could have revised the timeline from (2H 2015 or early 2016) to (2016), but anyways, we will have more info at q4 cc.
Sentiment: Strong Buy
Are you trying to say that MTD may not have been reached yet ?
How else can you interpret "Expansion trials at MTD initiated in targeted patients" ?
Can you please share q3 and q4 sales / rx no. for $XNPT's Horizant?
The company is up for sale and the price is gonna hinge upon the sales of Horizant.
You can share it here or XNPT board.
Jan: Expansion trials at MTD initiated in targeted patients (2H 2015 or early 2016)
Feb: Expansion trials at MTD initiated in targeted patients
Conclusion: We have reached MTD
Jan: Efficacy data for EC1169 and EC1456 (couple indications) by mid 2016
Feb: Efficacy data for EC1169 and EC1456 (couple indications)
Conclusion: we may see the data earlier or later than mid-16 (i guess they will share some data during q4 earnings call which typically happens in last week of Feb or 1st week of March)
There was good open market purchase below $3 by an insider few weeks ago, that speaks volumes about how management feels about the future of pps/company/EC1456/rest of the pipeline.
"according to the last CC, they stated that testing site manager were "excited" about their drug and they had to turn test patients away."
Well that sounds great but i haven't came across such thing. Can you please cite exactly when did they said this things?
Mylan paid some 75-80% premium to acquire MEDA which could have been 30-40% if markets didn't melt down in past few months.
I m trying to say that current PPS of XNPT may force the street underestimate the upside potential in a BO scenario. This shall go for $8+ in a month or two....